CRISPR Therapeutics (CRSP)

• Zugo-cel, an investigational allogeneic CAR T therapy, demonstrated encouraging preliminary data in autoimmune diseases, with four patients showing deep B-cell depletion and significant clinical improvement, including one systemic lupus erythematosus (SLE) patient achieving DORIS remission through Month 6.
• In relapsed or refractory (R/R) large B-cell lymphoma (LBCL), zugo-cel showed an overall response rate (ORR) of 90% and a complete response rate (CRR) of 70% at the 600 million cell dose, with 67% of patients remaining in complete response after one year.
• CRISPR Therapeutics initiated a new Phase 1 basket trial for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA) and established a collaboration with Lilly to evaluate zugo-cel with pirtobrutinib for aggressive B-cell lymphomas.
• Additional updates on zugo-cel across autoimmune disease and hematological malignancies are anticipated in the second half of 2026.

• CRISPR Therapeutics reported a strong launch for CASGEVY, with Vertex projecting over $100 million in revenues in 2025 and significant growth in 2026, and approximately 300 patients initiating the patient journey.
• The company maintains a strong financial position with $1.94 billion on its balance sheet and anticipates 2025 to be the peak spending year for the CASGEVY program.
• Key pipeline programs are advancing, including CTX310, which showed a 55% reduction in triglycerides and 50% reduction in LDL, and the Factor XI program with a major de-risking study readout expected in the second half of 2026.
• An update on cell therapy, including initial data for CTX112 in autoimmune disease and additional oncology data, is expected by year-end.

• CRISPR Therapeutics reported a strong financial position with $1.94 billion on its balance sheet.
• The CASGEVY launch is progressing well, with Vertex projecting over $100 million in revenues in 2025 and significant growth in 2026, with nearly 300 patients initiating the journey.
• Key pipeline updates include the CTX310 program showing 55% reduction in triglycerides and 50% reduction in LDL , and the Factor XI program expecting several de-risking readouts in the next 12 months, with a TKA study readout anticipated in the second half of 2026.
• The company anticipates a cell therapy update by year-end 2025 for oncology and autoimmune disease, including initial results for CTX112 in autoimmune disease.
• The CTX320 program for Lp(a) is awaiting the Horizon trial readout next year to inform its development path.

• CASGEVY is performing well, with Vertex reporting over $100 million in revenues in 2025 and significant growth in 2026, with nearly 300 patients initiating the patient journey. CRISPR anticipates a multi-billion dollar opportunity and expects revenues from the program to buffer company spend long-term.
• The pipeline is progressing, with the CTX310 program showing 55% reduction in triglycerides and 50% reduction in LDL in the overall cohort. A Factor XI TKA study readout is expected in the second half of 2026 , and initial results for CTX112 in autoimmune disease are anticipated by year-end.
• The CTX320 (Lp(a)) program is ongoing, but its advancement is paused pending the Horizon trial readout next year to inform optimal dosing and patient populations.
• CRISPR Therapeutics maintains a strong financial position with $1.94 billion on the balance sheet , and 2025 is expected to be the max spend year for the CASGEVY program.

CRISPR Therapeutics AG announced its financial results for the third quarter ended September 30, 2025, reporting a net loss and maintaining a strong cash position. CASGEVY® is showing accelerating momentum, with nearly 300 patients referred, approximately 165 patients completing their first cell collection, and 39 patients having received infusions globally as of September 30, 2025. Vertex expects over $100 million in total CASGEVY revenue this year and significant growth in 2026. The company provided updates on its diverse pipeline, including positive Phase 1 data for CTX310®, ongoing clinical trials for CTX112™ and SRSD107, and plans to initiate a clinical trial for CTX460™ in mid-2026.